Advertisement
UK markets closed

  • FTSE 100

    8,164.12
    -15.56 (-0.19%)
     

  • FTSE 250

    20,286.03
    -45.77 (-0.23%)
     

  • AIM

    764.38
    -0.09 (-0.01%)
     

  • GBP/EUR

    1.1796
    -0.0009 (-0.07%)
     

  • GBP/USD

    1.2646
    +0.0005 (+0.04%)
     

  • Bitcoin GBP

    48,705.26
    +601.78 (+1.25%)
     

  • CMC Crypto 200

    1,265.73
    -18.10 (-1.41%)
     

  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     

  • DOW

    39,118.86
    -45.20 (-0.12%)
     

  • CRUDE OIL

    81.46
    -0.28 (-0.34%)
     

  • GOLD FUTURES

    2,336.90
    +0.30 (+0.01%)
     

  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     

  • HANG SENG

    17,718.61
    +2.14 (+0.01%)
     

  • DAX

    18,235.45
    +24.90 (+0.14%)
     

  • CAC 40

    7,479.40
    -51.32 (-0.68%)
     
Property :

8 UK holiday home businesses you could buy now

A holiday let could be a very sound investment, providing a decent income, capital growth and — somewhere to escape

Leveraging AI in Drug Discovery: Elizabeth Schwarzbach of BigHat Biosciences, Live from NYSE

IPO Edge
·1-min read

IPO Edge hosted a fireside chat from the floor of the New York Stock Exchange with Elizabeth Schwarzbach,  Chief Business Officer of BigHat Biosciences. She spoke to  IPO Edge Editor-in-Chief John Jannarone about the mission of BigHat Biosciences, how AI and Machine Learning are used in drug discovery, major investors including Andreesen Horowitz and Bristol-Myers Squibb Co., the unique skills sets of BigHat’s staff and much more.  Watch the full recording below:

About BigHat Biosciences

Developer of antibodies experimental platform designed to empower biological antibodies and other therapeutic proteins. The company’s platform is agile, multi-objective, data-driven, and integrates a wet laboratory with artificial intelligence/machine learning techniques to design antibodies, enabling drug developers to create antibodies and undertake novel biotherapeutic designs.

ADVERTISEMENT

About Elizabeth Schwarzbach

Elizabeth has over 20 years of experience in biopharma and academia drug discovery and development. She found her passion for pharmacology as a biologist in Merck Research Labs, later completing her doctorate in neuropharmacology at the University of Pennsylvania School of Medicine. After gaining growth, portfolio, and investment strategy experience at L.E.K. Consulting’s Life Sciences practice, she transitioned to GlaxoSmithKline R&D Strategy team. Most recently, Elizabeth served as the Chief Business Officer at the New York Stem Cell Foundation (NYSCF) Research Institute.

Contact:

IPO-Edge.com

Editor@ipo-edge.com